XOMA’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a $117.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th.

XOMA Trading Up 1.6 %

Shares of XOMA stock opened at $29.12 on Wednesday. The company has a fifty day moving average price of $28.07 and a two-hundred day moving average price of $26.29. XOMA has a one year low of $14.27 and a one year high of $30.50. The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15.

XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative net margin of 128.59% and a negative return on equity of 24.50%. The firm had revenue of $11.09 million during the quarter, compared to analyst estimates of $8.37 million. On average, research analysts anticipate that XOMA will post -1.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ellsworth Advisors LLC bought a new stake in shares of XOMA during the third quarter worth approximately $516,000. Rhumbline Advisers boosted its stake in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in XOMA during the 1st quarter worth $212,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,266 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.